Participants in the T1D Exchange Clinic Network retained the ability to secrete an incompletely processed form of insulin, even when their diabetes was longstanding. The results, generated in part from T1D Exchange Biobank data and samples, suggest a story of how type 1 diabetes might progress.
We think of glucagon as a medication to treat lows, part of our emergency kits. But what if we could change the way our body uses glucagon to actually manage our highs and lows? New research suggests that might be possible.